ENKAM Pharmaceuticals A/S

Enkam’s novel lead development candidate, FGLs, is a peptide that has demonstrated positive effects in animal models indicating disease modification with a direct improvement of cognition in patients with Alzheimer’s disease and a fast onset of anti-depression effects in depressed patients. The European Union awarded a fourth grant of €6 million to an Enkam-led consortium following extensive peer review to fund a proof-of-concept clinical trial for the treatment of patients with Alzheimer’s disease and the IND enabling pre-clinical program is well underway.